提高药物研发中心血管毒性的预测性研究进展
发布时间：2018-08-06 07:49
【摘要】：心血管风险仍然是导致新药研发终止、发生严重不良反应甚至撤离市场的主要因素。虽然心肌离子通道检测、动作电位检测和遥测技术的运用大大提高了对药物诱导心律失常的预测的准确性,并且降低了安全风险,但对药物引起的其他心脏毒性如心肌收缩功能异常、心肌缺血、心肌损伤及心衰等仍缺乏有效的检测方法和技术,而目前在药物研发阶段对这些心血管安全风险没有像心律失常一样引起足够的关注。本文综述了近期的研究进展,全面阐述在药物研发阶段及临床应用中主要的心血管风险、如何检测这些风险以及现有安全评价手段的准确性和预测性和新方法新技术的研究与运用等。
[Abstract]:Cardiovascular risk is still the main factor leading to the termination of new drug development, serious adverse reactions and even withdrawal from the market. Although the use of myocardial ion channel detection, action potential detection and telemetry techniques has greatly improved the accuracy of prediction of drug-induced arrhythmias and reduced the risk of safety. However, there is still a lack of effective methods and techniques for the detection of other cardiotoxicity induced by drugs, such as abnormal myocardial contractility, myocardial ischemia, myocardial injury and heart failure. These cardiovascular safety risks have not received as much attention as arrhythmias in the drug development phase. This article reviews the recent research progress and comprehensively describes the major cardiovascular risks in the drug development phase and clinical application. How to detect these risks, as well as the accuracy and predictability of existing safety assessment methods and the research and application of new methods and new technologies, etc.
【作者单位】： 康龙化成(北京)新药技术股份有限公司;
【分类号】：R95
本文编号：2167010
[Abstract]:Cardiovascular risk is still the main factor leading to the termination of new drug development, serious adverse reactions and even withdrawal from the market. Although the use of myocardial ion channel detection, action potential detection and telemetry techniques has greatly improved the accuracy of prediction of drug-induced arrhythmias and reduced the risk of safety. However, there is still a lack of effective methods and techniques for the detection of other cardiotoxicity induced by drugs, such as abnormal myocardial contractility, myocardial ischemia, myocardial injury and heart failure. These cardiovascular safety risks have not received as much attention as arrhythmias in the drug development phase. This article reviews the recent research progress and comprehensively describes the major cardiovascular risks in the drug development phase and clinical application. How to detect these risks, as well as the accuracy and predictability of existing safety assessment methods and the research and application of new methods and new technologies, etc.
【作者单位】： 康龙化成(北京)新药技术股份有限公司;
【分类号】：R95
【相似文献】
相关期刊论文 前6条
1 孔丹莉;二硫化碳对心血管毒性的研究进展[J];湖北预防医学杂志;1999年06期
2 王晓芹,解好群,金远林;阿霉素引起心血管毒性反应19例[J];青海医药杂志;2001年05期
3 姜岳明,张振明,迟晓文;锰的心血管毒性[J];铁道劳动安全卫生与环保;2001年04期
4 任少华;可卡因的心血管毒性作用[J];国外医学(心血管疾病分册);1996年01期
5 王海燕;;可卡因滥用的心血管毒性[J];新医学;2010年10期
6 赵晶;江伟;;布比卡因心血管毒性机制及治疗的研究进展[J];临床麻醉学杂志;2008年05期
相关硕士学位论文 前1条
1 黄海金;米力农与肾上腺素逆转布比卡因心血管毒性的比较研究[D];南昌大学;2008年
，本文编号：2167010
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2167010.html
最近更新
教材专著
